Minamisawa M, et al. - In this secondary analysis of a cardiac subpopulation from the phase 3 APOLLO study, researchers assessed how patisiran, an RNA interference therapeutic, effects regional left ventricular (LV) myocardial strain in cardiac manifestation in hereditary transthyretin-mediated (hATTR) amyloidosis, an autosomal dominant, progressive, and life-threatening disease. According to findings, worsening of LV global longitudinal strain (GLS) was prevented by patisiran over 18 months, driven mainly by reducing the progression of disease in the basal region. So basal longitudinal strain could be a more sensitive marker of cardiac manifestation associations in hATTR amyloidosis, and basal region, more than other ventricular regions, may be more influenced by disease-modifying therapies.